Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...

We recently published a list of 10 Best Beaten Down Stocks to Buy According to Analysts. In this article, we are going to ...

KKR has abandoned a private equity consortium discussing a takeover of Gerresheimer AG , Bloomberg News reported on Thursday, ...

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

Helge Lund told the board he planned to stand down 'most likely during 2026' having chaired the firm since 2019.

If these findings are confirmed in humans, it could have implications for treating many diseases where the immune system ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an ...

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...

Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Lexicon's LX9851 targets ACSL5, a liver enzyme involved in fat metabolism that helps moderate fat accumulation and slow down ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...